Developer docs
API playgroundTry for free, no card

Search company profiles

Altoida

Full company profile

uuid0000pm8

Namestring
Altoida
Legal namestring
Altoida, Inc.
Websiteurl
altoida.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Altoida, Inc. is a Washington, DC-based, privately held digital diagnostics company developing an AI- and augmented reality-powered Digital NeuroMarker Platform for early detection of Mild Cognitive Impairment (MCI) and Alzheimer's disease. The core offering is a 10-minute, self-administered tablet-based assessment that captures multimodal sensor data (accelerometer, gyroscope, touchscreen, AR interactions, speech) as users complete neuroscience-driven tasks simulating instrumental activities of daily living. This data feeds proprietary machine learning models called Digital Neuro Signatures (DNS) that produce a 0-100 score distinguishing cognitively normal from cognitively impaired individuals, with published evidence of 94% accuracy in predicting Alzheimer's disease conversion within 12 months and validation in Nature Digital Medicine.

The platform combines augmented reality, sensor fusion, and explainable AI, has been validated across more than 42,000 tests and 20,000+ participants over 20+ years of research, and received FDA Breakthrough Device Designation in 2021 for its first predictive ML algorithm. A DNS-MCI algorithm patent is filed-pending, and the platform is positioned for extension into Parkinson's, TBI, and depression indications. SOC 2 Type II and ISO 27001 certifications support enterprise readiness.

Altoida pursues a B2B enterprise go-to-market targeting pharmaceutical companies for clinical trial enrichment and patient selection (anchored by Eisai's 5-year multi-center Alzheimer's study), cognitive care specialty providers such as Mindspan for care pathway integration, and academic research institutions. The company is pre-commercial: the platform is investigational only, not FDA cleared, and not available for sale. Anticipated revenue streams upon clearance include platform licensing and royalties to pharma, subscription-based clinical diagnostics services to healthcare systems, and research partnership income. Approximately $24.7M has been raised across nine funding rounds through Series A ($20.3M total, 2022), led by M Ventures (Merck KGaA's strategic CVC arm) and Whitecap Venture Partners, with additional backing from Hikma Ventures, Eisai Innovation, and the Alzheimer's Drug Discovery Foundation.

Short descriptiontext

Altoida develops an AI- and augmented reality-powered Digital NeuroMarker Platform that delivers a 10-minute self-administered cognitive assessment for early detection of Mild Cognitive Impairment and Alzheimer's disease, serving pharmaceutical companies, healthcare providers, and research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital cognitive assessment, neurodegenerative diagnostics, brain health platform, digital biomarkers, clinical trial enrichment
Industry3 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Neurological Diagnostics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing to Pharma
TypeLicensing Royalties
Description

Licensing the investigational platform to pharmaceutical companies for incorporation into CNS clinical trials, supporting patient selection, treatment monitoring, and disease progression research.

altoida.com
2Clinical Diagnostics Services
TypeSubscription Recurring
Description

Providing cognitive assessment services to healthcare systems and clinical care settings once FDA cleared. Platform intended for clinical use in primary care and specialty neurology settings.

altoida.com
3Research Partnerships
TypeProfessional Services
Description

Research partnerships with pharmaceutical companies like Eisai for collaborative studies and clinical exploration, including the 5-year multi-center Alzheimer's study.

startupticker.ch
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Investigational use only - not commercially available
ModelOtherBilling cadenceMulti-year contract
Notes

Platform is in clinical trial and research partnership phase. No commercial pricing available as the platform has not received FDA clearance or approval for commercial sale.

altoida.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1NeuroMarker Platform
Description

AI and augmented reality-powered digital platform designed to rapidly detect early cognitive decline and assess brain health through multimodal digital biomarkers.

altoida.com
+2 more records
Core offering1 text field

Altoida develops and provides the Digital NeuroMarker Platform, an AI- and augmented reality-powered digital cognitive assessment that delivers a 10-minute, self-administered test on a smart tablet to capture hundreds of multimodal digital biomarkers (motor, speech, AR, and cognitive data). The platform produces a Digital Neuro Signature (DNS) score (0-100) to detect Mild Cognitive Impairment (MCI) and predict conversion to Alzheimer's disease. The product is currently offered for investigational use and clinical trial enrichment to pharmaceutical and biotech partners, with planned clinical adoption in healthcare systems upon FDA clearance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 94% accuracy in predicting Alzheimer's disease within one year
+4 more records
Product overview1 text field

Altoida offers a unified Digital NeuroMarker Platform centered around its AI and AR-powered cognitive assessment technology. The core offering consists of a 10-minute, tablet-based Digital Cognitive Assessment that uses augmented reality to simulate daily living activities while capturing multimodal sensor data. This data feeds into proprietary machine learning models called Digital Neuro Signatures (DNS) that generate scores for detecting Mild Cognitive Impairment and Alzheimer's disease. The platform is designed for both in-clinic and remote administration, targeting healthcare providers, pharmaceutical companies for clinical trials, and research institutions.

Product and service3 records
1Digital NeuroMarker Platform
CategoryNeurodiagnostic Software Platform
Description

Multi-modal AI and AR-powered platform delivering a 10-minute, self-administered cognitive assessment that captures hundreds of digital biomarkers across motor, speech, AR, and cognitive domains to detect Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier than traditional methods. Designed for healthcare providers, pharmaceutical clinical trials, and research institutions.

2Digital Cognitive Assessment
CategoryCognitive Assessment Application
Description

A 10-minute self-administered assessment using a smart tablet that leverages augmented reality to simulate activities of daily living while capturing motion, speech, and touch data for objective cognitive evaluation. Currently investigational use only.

3Digital Neuro Signature (DNS)
CategoryAI Diagnostic Algorithm
Description

Machine learning model trained on multimodal sensor data that generates an ordinal DNS score (0-100) to distinguish cognitively normal from cognitively impaired participants. Filed as a pending patent (inventions/methods).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Research collaboration to evaluate integration of Altoida's AI/AR-powered digital NeuroMarker platform into Mindspan's personalized cognitive care delivery model. Pilot study enrolling up to 100 adults to assess clinical, operational, and economic impacts.

2RADAR-AD Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-19
Description

European project funded by Innovative Medicines Initiative (IMI) evaluating remote monitoring technologies including Altoida's AR digital cognitive assessment for early identification of Alzheimer's Disease. Published in Nature Digital Medicine.

altoida.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-10-24
Description

Dual-center clinical study sites for 188-participant cross-sectional study validating Altoida's digital cognitive assessment against standard neuropsychological tests.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-18
Description

Academic collaboration for the 5-year multi-center Alzheimer's study conducted with Eisai, advancing research into the Alzheimer's Disease continuum.

5Eisai
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-07-09
Description

Research partnership focused on developing predictive diagnostics for neurodegenerative diseases like Alzheimer's. Includes financing and collaboration on the 5-year multi-center Alzheimer's study launched in October 2023 with Ionian University.

startupticker.ch
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Commercial-stage diagnostics company offering PrecivityAD blood-based Alzheimer's biomarker tests. Comparable in targeting early Alzheimer's detection for clinical decision-making and pharma trial enrichment, though using a different modality (blood biomarkers vs. Altoida's digital biomarkers).

TypeEmerging player
Description

Digital cognitive assessment platform delivering rapid, tablet-based cognitive testing for clinicians. Comparable in targeting the same primary-care and specialty workflow pain points Altoida addresses, though focused on broader cognitive domains rather than AR-based neurocognitive biomarkers.

TypeBroad incumbent
Description

Public company offering ultra-sensitive biomarker measurement platforms (Simoa) used in Alzheimer's and neurodegenerative disease research and diagnostics. Comparable as a neurology biomarker platform serving pharma and clinical research customers, though operating in the blood-based biomarker modality rather than digital.

TypeDirect peer
Description

Public UK-based digital cognitive assessment company with the CANTAB battery used in research and clinical trials. Directly comparable to Altoida in addressing pharmaceutical CNS trial enrichment and clinical cognitive assessment, with overlapping customer base and regulatory positioning.

TypeEmerging player
Description

Digital health company developing cognitive assessment and Alzheimer's risk tools for consumers and clinical use. Comparable in targeting early detection of cognitive decline through digital means, though with a stronger consumer-facing orientation than Altoida's clinical/research focus.

TypeBroad incumbent
Description

Large biotech with leading Alzheimer's franchise (Aduhelm/Leqembi partnership). Comparable as a major incumbent shaping Alzheimer's diagnostic and therapeutic standards, and as a potential enterprise customer or competitor for diagnostic partnerships in pharma clinical trials.

TypeDirect peer
Description

Public digital cognitive assessment company providing computerized tests for clinical trials and healthcare. Cogstate is the closest direct peer to Altoida, sharing the same digital cognitive assessment value proposition for pharma trial enrichment and clinical use, with an established commercial footprint Altoida is still building toward.

8Eisai
TypeOthers
Description

Global pharmaceutical company that is both an Altoida investor and research partner, with major Alzheimer's franchise (Leqembi). Relevant as the pharma incumbent defining the Alzheimer's treatment landscape in which Altoida's diagnostic platform operates, and as a strategic capital and commercialization partner.

TypeBroad incumbent
Description

Global pharma with the Kisunla Alzheimer's therapy and active R&D into Alzheimer's diagnostics (including blood-based biomarker programs). Comparable as a broad incumbent defining the Alzheimer's treatment and diagnostic landscape in which Altoida's platform competes for pharma trial enrichment partnerships.

TypeEmerging player
Description

Boston-based digital health company offering AI-powered cognitive assessment (including DCTclock) for early detection of cognitive impairment. Directly comparable in targeting MCI/Alzheimer's early detection with digital tools, though with different technology stack (pen-and-digitizer vs. Altoida's AR-based approach).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altoida

Digital Neurological Diagnosticsaltoida.com

Altoida develops an AI- and augmented reality-powered Digital NeuroMarker Platform that delivers a 10-minute self-administered cognitive assessment for early detection of Mild Cognitive Impairment and Alzheimer's disease, serving pharmaceutical companies, healthcare providers, and research institutions.

What Altoida does

Altoida, Inc. is a Washington, DC-based, privately held digital diagnostics company developing an AI- and augmented reality-powered Digital NeuroMarker Platform for early detection of Mild Cognitive Impairment (MCI) and Alzheimer's disease. The core offering is a 10-minute, self-administered tablet-based assessment that captures multimodal sensor data (accelerometer, gyroscope, touchscreen, AR interactions, speech) as users complete neuroscience-driven tasks simulating instrumental activities of daily living. This data feeds proprietary machine learning models called Digital Neuro Signatures (DNS) that produce a 0-100 score distinguishing cognitively normal from cognitively impaired individuals, with published evidence of 94% accuracy in predicting Alzheimer's disease conversion within 12 months and validation in Nature Digital Medicine.

The platform combines augmented reality, sensor fusion, and explainable AI, has been validated across more than 42,000 tests and 20,000+ participants over 20+ years of research, and received FDA Breakthrough Device Designation in 2021 for its first predictive ML algorithm. A DNS-MCI algorithm patent is filed-pending, and the platform is positioned for extension into Parkinson's, TBI, and depression indications. SOC 2 Type II and ISO 27001 certifications support enterprise readiness.

Altoida pursues a B2B enterprise go-to-market targeting pharmaceutical companies for clinical trial enrichment and patient selection (anchored by Eisai's 5-year multi-center Alzheimer's study), cognitive care specialty providers such as Mindspan for care pathway integration, and academic research institutions. The company is pre-commercial: the platform is investigational only, not FDA cleared, and not available for sale. Anticipated revenue streams upon clearance include platform licensing and royalties to pharma, subscription-based clinical diagnostics services to healthcare systems, and research partnership income. Approximately $24.7M has been raised across nine funding rounds through Series A ($20.3M total, 2022), led by M Ventures (Merck KGaA's strategic CVC arm) and Whitecap Venture Partners, with additional backing from Hikma Ventures, Eisai Innovation, and the Alzheimer's Drug Discovery Foundation.

Altoida firmographics

Firmographics
Name
Altoida
Legal name
Altoida, Inc.
Website
https://altoida.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Altoida develops an AI- and augmented reality-powered Digital NeuroMarker Platform that delivers a 10-minute self-administered cognitive assessment for early detection of Mild Cognitive Impairment and Alzheimer's disease, serving pharmaceutical companies, healthcare providers, and research institutions.
Ownership category
akta.pro rank

Altoida industry classification

Industry
Product category
Digital Neurological Diagnostics
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Digital cognitive assessment
  • Neurodegenerative diagnostics
  • Brain health platform
  • Digital biomarkers
  • Clinical trial enrichment

Where Altoida is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Altoida business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Platform Licensing to Pharma: Licensing the investigational platform to pharmaceutical companies for incorporation into CNS clinical trials, supporting patient selection, treatment monitoring, and disease progression research.
  2. Clinical Diagnostics Services: Providing cognitive assessment services to healthcare systems and clinical care settings once FDA cleared. Platform intended for clinical use in primary care and specialty neurology settings.
  3. Research Partnerships: Research partnerships with pharmaceutical companies like Eisai for collaborative studies and clinical exploration, including the 5-year multi-center Alzheimer's study.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInvestigational use only - not commercially available

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Altoida product offering

Product offering

Core offering

Altoida develops and provides the Digital NeuroMarker Platform, an AI- and augmented reality-powered digital cognitive assessment that delivers a 10-minute, self-administered test on a smart tablet to capture hundreds of multimodal digital biomarkers (motor, speech, AR, and cognitive data). The platform produces a Digital Neuro Signature (DNS) score (0-100) to detect Mild Cognitive Impairment (MCI) and predict conversion to Alzheimer's disease. The product is currently offered for investigational use and clinical trial enrichment to pharmaceutical and biotech partners, with planned clinical adoption in healthcare systems upon FDA clearance.

Product overview

Altoida offers a unified Digital NeuroMarker Platform centered around its AI and AR-powered cognitive assessment technology. The core offering consists of a 10-minute, tablet-based Digital Cognitive Assessment that uses augmented reality to simulate daily living activities while capturing multimodal sensor data. This data feeds into proprietary machine learning models called Digital Neuro Signatures (DNS) that generate scores for detecting Mild Cognitive Impairment and Alzheimer's disease. The platform is designed for both in-clinic and remote administration, targeting healthcare providers, pharmaceutical companies for clinical trials, and research institutions.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroMarker Platform: AI and augmented reality-powered digital platform designed to rapidly detect early cognitive decline and assess brain health through multimodal digital biomarkers.
  • Digital NeuroMarker Platform
  • Digital Neuro Signature (DNS)

Products and services

  • Digital NeuroMarker Platform Multi-modal AI and AR-powered platform delivering a 10-minute, self-administered cognitive assessment that captures hundreds of digital biomarkers across motor, speech, AR, and cognitive domains to detect Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier than traditional methods. Designed for healthcare providers, pharmaceutical clinical trials, and research institutions.
  • Digital Cognitive Assessment A 10-minute self-administered assessment using a smart tablet that leverages augmented reality to simulate activities of daily living while capturing motion, speech, and touch data for objective cognitive evaluation. Currently investigational use only.
  • Digital Neuro Signature (DNS) Machine learning model trained on multimodal sensor data that generates an ordinal DNS score (0-100) to distinguish cognitively normal from cognitively impaired participants. Filed as a pending patent (inventions/methods).

Quantifiable outcome

  • 94% accuracy in predicting Alzheimer's disease within one year
  • +4 more outcomes

Companies that use Altoida

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Altoida technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Altoida partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and supporting.

  • MindspanflagshipStrategic or Co-development Partner · 13 January 2026Research collaboration to evaluate integration of Altoida's AI/AR-powered digital NeuroMarker platform into Mindspan's personalized cognitive care delivery model. Pilot study enrolling up to 100 adults to assess clinical, operational, and economic impacts.
  • RADAR-AD ConsortiumcoreStrategic or Co-development Partner · 19 December 2023European project funded by Innovative Medicines Initiative (IMI) evaluating remote monitoring technologies including Altoida's AR digital cognitive assessment for early identification of Alzheimer's Disease. Published in Nature Digital Medicine.
  • Hospital Clinic Barcelona & Barcelona-Beta Brain Research CentersupportingStrategic or Co-development Partner · 24 October 2023Dual-center clinical study sites for 188-participant cross-sectional study validating Altoida's digital cognitive assessment against standard neuropsychological tests.
  • Ionian UniversitycoreStrategic or Co-development Partner · 18 October 2023Academic collaboration for the 5-year multi-center Alzheimer's study conducted with Eisai, advancing research into the Alzheimer's Disease continuum.
  • EisaiflagshipStrategic or Co-development Partner · 9 July 2021Research partnership focused on developing predictive diagnostics for neurodegenerative diseases like Alzheimer's. Includes financing and collaboration on the 5-year multi-center Alzheimer's study launched in October 2023 with Ionian University.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Altoida competitors and assessment

Company assessment

Emerging players

  • C2N Diagnostics: Commercial-stage diagnostics company offering PrecivityAD blood-based Alzheimer's biomarker tests. Comparable in targeting early Alzheimer's detection for clinical decision-making and pharma trial enrichment, though using a different modality (blood biomarkers vs. Altoida's digital biomarkers).
  • BrainCheck: Digital cognitive assessment platform delivering rapid, tablet-based cognitive testing for clinicians. Comparable in targeting the same primary-care and specialty workflow pain points Altoida addresses, though focused on broader cognitive domains rather than AR-based neurocognitive biomarkers.
  • Neurotrack: Digital health company developing cognitive assessment and Alzheimer's risk tools for consumers and clinical use. Comparable in targeting early detection of cognitive decline through digital means, though with a stronger consumer-facing orientation than Altoida's clinical/research focus.
  • Linus Health: Boston-based digital health company offering AI-powered cognitive assessment (including DCTclock) for early detection of cognitive impairment. Directly comparable in targeting MCI/Alzheimer's early detection with digital tools, though with different technology stack (pen-and-digitizer vs. Altoida's AR-based approach).

Broad incumbents

  • Quanterix: Public company offering ultra-sensitive biomarker measurement platforms (Simoa) used in Alzheimer's and neurodegenerative disease research and diagnostics. Comparable as a neurology biomarker platform serving pharma and clinical research customers, though operating in the blood-based biomarker modality rather than digital.
  • Biogen: Large biotech with leading Alzheimer's franchise (Aduhelm/Leqembi partnership). Comparable as a major incumbent shaping Alzheimer's diagnostic and therapeutic standards, and as a potential enterprise customer or competitor for diagnostic partnerships in pharma clinical trials.
  • Eli Lilly: Global pharma with the Kisunla Alzheimer's therapy and active R&D into Alzheimer's diagnostics (including blood-based biomarker programs). Comparable as a broad incumbent defining the Alzheimer's treatment and diagnostic landscape in which Altoida's platform competes for pharma trial enrichment partnerships.

Direct peers

  • Cambridge Cognition: Public UK-based digital cognitive assessment company with the CANTAB battery used in research and clinical trials. Directly comparable to Altoida in addressing pharmaceutical CNS trial enrichment and clinical cognitive assessment, with overlapping customer base and regulatory positioning.
  • Cogstate: Public digital cognitive assessment company providing computerized tests for clinical trials and healthcare. Cogstate is the closest direct peer to Altoida, sharing the same digital cognitive assessment value proposition for pharma trial enrichment and clinical use, with an established commercial footprint Altoida is still building toward.

Others

  • Eisai: Global pharmaceutical company that is both an Altoida investor and research partner, with major Alzheimer's franchise (Leqembi). Relevant as the pharma incumbent defining the Alzheimer's treatment landscape in which Altoida's diagnostic platform operates, and as a strategic capital and commercialization partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Altoida social profiles

Digital presence

Altoida compliance and trust

Trust signal

Compliance2 records

Altoida financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altoida leadership team

Management profile

Number of profiles

Profiles9 records

Altoida funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altoida M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altoida

What does Altoida do?

Altoida develops and provides the Digital NeuroMarker Platform, an AI- and augmented reality-powered digital cognitive assessment that delivers a 10-minute, self-administered test on a smart tablet to capture hundreds of multimodal digital biomarkers (motor, speech, AR, and cognitive data). The platform produces a Digital Neuro Signature (DNS) score (0-100) to detect Mild Cognitive Impairment (MCI) and predict conversion to Alzheimer's disease. The product is currently offered for investigational use and clinical trial enrichment to pharmaceutical and biotech partners, with planned clinical adoption in healthcare systems upon FDA clearance.

Is Altoida a public or private company?

Altoida is a private company. It is classified as venture growth investor backed and is currently operating.

When was Altoida founded?

Altoida was founded in 2005. It employs 11 to 50 people.

Where is Altoida based?

Altoida is headquartered in Washington, United States, in the North America region.

How does Altoida make money?

Three revenue lines are on record. Platform Licensing to Pharma is the primary driver. The others are clinical Diagnostics Services and research Partnerships.

Who are Altoida's main competitors?

Emerging players on record are C2N Diagnostics, BrainCheck, Neurotrack and Linus Health. Broad incumbents are Quanterix, Biogen and Eli Lilly. Direct peers are Cambridge Cognition and Cogstate. Eisai is listed as an others.

Does Altoida have an API?

No public API is recorded for Altoida.

What industry is Altoida in?

Altoida's product category is Digital Neurological Diagnostics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyTwo very different Alzheimer’s tests just teamed upCircular Genomics and Altoida announced a collaboration to combine a blood test and a 10-minute cognitive app for earlier Alzheimer's detection. The workflow targets 200 million undiagnosed mild cognitive impairment cases, with real-world pilots expected later this year. Altoida's platform remains investigational and has not received FDA clearance.Longevity.TechnologyCircular Genomics, Altoida partner on multimodal Alzheimer’s testingCircular Genomics and Altoida announced a collaboration to combine blood-based circular RNA biomarkers with Altoida's AI-powered Digital NeuroMarker for Alzheimer's testing. The alliance aims to pair digital cognitive measures with blood signatures for early identification and patient stratification. Altoida is preparing a pivotal study intended to support FDA clearance.PR NewswireCircular Genomics and Altoida Announce Collaboration to Advance First-of-Kind Multimodal Precision Medicine for Alzheimer's DiseaseCircular Genomics and Altoida announced a collaboration combining blood-based circRNA biomarkers with AI-powered digital cognitive assessments to advance Alzheimer's drug development and frontline care. The partnership aims to create a multimodal diagnostic workflow, with real-world evidence studies planned and pilots expected later this year.LinkedInAltoida, Inc.Altoida, Inc. is presenting its AI/AR-powered Digital NeuroMarker Platform at BIO2025 and RESI2025 to detect early cognitive decline. The tablet-enabled, 10-minute self-administered assessment aims to replace outdated diagnostic tools and support disease-modifying therapies.Neurology liveData Evolution in Alzheimer Disease: Is the Future Digital?This article explores how digital biomarkers collected through wearable devices and smartphones are emerging as tools for earlier diagnosis, monitoring, and management of Alzheimer disease, with experts noting that passive data such as gait speed, speech patterns, and heart rate variability can indicate early cognitive decline. Research initiatives like the Altoida device (the only AD-specific digital biomarker tool with FDA approval and CE marking), the Evidation Health partnership with Apple and Eli Lilly that generated 16 terabytes of data, and the UK GameChanger project are cited as examples of active development in this field. Experts highlight that while challenges remain including clinical validation, regulatory approval, and data privacy concerns, digital biomarkers show promise in revolutionizing AD detection, monitoring high-risk individuals, optimizing clinical trials, and potentially enabling digital therapeutic interventions.openPR.comDigital Biomarkers Market to Reach US$ 39.28 Billion by 2033 as Wearables, Remote Monitoring and AI-Driven Clinical Insights Gain Wider AdoptionThe global Digital Biomarkers Market reached US$ 6.18 billion in 2025 and is projected to grow to US$ 39.28 billion by 2033, representing a compound annual growth rate of 22.7% during the forecast period 2026-2033, as healthcare and life sciences organizations increasingly adopt digitally captured physiological, behavioral, and functional signals for diagnosis, monitoring, and treatment development. Empatica Inc announced FDA clearances for its pulse oximetry algorithm with a Predetermined Change Control Plan and new cardiac digital biomarkers, alongside the launch of EmbraceMini, described as the world's smallest actigraphy wearable for clinical trials, while Koneksa, Evidation, and Altoida highlighted advances in clinical-trial support platforms, real-world multimodal datasets, and neurological disease assessment tools. The market's expansion is driven by the growing ability of wearables, sensors, mobile applications, and integrated analytics platforms to generate continuous real-world health data outside traditional clinical settings, with competition increasingly shaped by validation, regulatory credibility, and the ability to generate clinically meaningful data in real-world settings.EIN PresswireDigital Biomarkers Market Growth Accelerates at 22.1% CAGR Through 2033 | Persistence Market ResearchThe global digital biomarkers market is projected to grow from US$4.6 billion in 2026 to US$18.7 billion by 2033, representing a 22.1% CAGR, driven by wearable adoption, AI advancements, aging populations, and rising chronic disease prevalence. North America currently leads the market with 45.5% share in 2025, supported by FDA regulatory frameworks and Medicare reimbursements, while Asia-Pacific is emerging as the fastest-growing region. Key industry developments include ActiGraph's acquisition of Biofourmis Life Sciences to enhance decentralized clinical trials and Altoida's AI cognitive assessment partnership with Mindspan.PrivatevisionsProyectos privados que enfrentan el Alzheimer – Private VisionsPrivate donors and tech philanthropists are funding a wave of neurotechnology innovations aimed at combating Alzheimer's disease, which affects over 55 million people worldwide according to the WHO. Multiple startups are developing AI-based tools for early prediction and brain stimulation technologies, including Cognito Therapeutics testing light and sound stimulation to reduce toxic protein accumulation, Altoida using smartphone sensors to detect Alzheimer's up to ten years before clinical diagnosis, and Neuralink exploring brain-computer interfaces for cognitive diseases. The Chan Zuckerberg Initiative is also funding interdisciplinary research combining cellular biology, AI, and big data to understand neural network degeneration.openPR.comDigital Biomarkers Market: Growth Trends, Key Players & Future Outlook 2025-2033 | Koneksa Health, Altoida Inc, Empatica Inc.The global digital biomarkers market reached US$4.16 billion in 2024 and is projected to reach US$26.69 billion by 2033, a CAGR of 22.7%. Growth is driven by AI, remote healthcare, and chronic disease prevalence, with challenges including data privacy and standardization. Recent partnerships include Biofourmis and Biogen's work on Parkinson's disease.